港股異動 | 新秀麗(1910.HK)大跌超1%創新低 績後遭機構大砍目標價
格隆匯3月23日丨新秀麗(1910.HK)近期公司股價持續下跌,今日再次大跌11.15%盤中創下歷史新低,現報5.42港元,暫成交7618萬港元,最新總市值77.64億港元。新秀麗日前公佈,2019年度股東佔溢利減少44.0%至1.33億美元。由於疫情帶來不明朗故暫不派息。業績公佈後遭機構唱淡。美銀美林發報告稱,將新秀麗2020/2021財年經調整每股盈利分別削66%及21%,目標價降17%,由15.2港元降至12.6港元。野村指出,將新秀麗今年及明年的純利預測分別下調87%及23%,目標價亦隨之下調62.5%,由16港元降至6港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.